Co-Authors
This is a "connection" page, showing publications co-authored by DANIEL J BOOSER and ABENAA BREWSTER.
Connection Strength
0.243
-
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83.
Score: 0.083
-
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112.
Score: 0.044
-
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-?. Invest New Drugs. 2018 12; 36(6):1103-1109.
Score: 0.042
-
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5.
Score: 0.026
-
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer. 2012 May 01; 118(9):2378-84.
Score: 0.026
-
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7909-16.
Score: 0.021